HIV Vaccine for Prevention and Cure, A Mission Possible
HIV/AIDS was once a highly deadly infective disease that killed the global people of a million annually two decades ago. While we are enjoying the HIV therapeutic advances (mostly important from HAART invention), one obvious drawback is still unresolved-unable to clearance all HIV from infected human bodies. As a result, a series of different therapeutic attempts have been proposed based on present knowledge of different features of HIV-induced pathogenesis and human mortalities. Facing this shortcoming, innovative designs and update of HIV vaccines and other types of HIV therapeutic inventions can be a final solution for completely HIV clearance and infection managements in human beings. Owing to these scientific and medical significances, several experimental and clinical attempts have to be made. Among these attempts, part of them (updating HIV vaccine developments and clinical routines) are quite promising and noteworthy. In this article, we offer the general information of this attempt and discuss it separately, especially on the respects of HIV vaccine strategic innovations..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Reviews on recent clinical trials - 11(2016), 4, Seite 290-296 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Da-Yong Lu [VerfasserIn] |
|---|
| Links: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1989982042 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1989982042 | ||
| 003 | DE-627 | ||
| 005 | 20230510075524.0 | ||
| 007 | tu | ||
| 008 | 170207s2016 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20170501 |
| 035 | |a (DE-627)OLC1989982042 | ||
| 035 | |a (DE-599)GBVOLC1989982042 | ||
| 035 | |a (PRQ)benthamscience_primary_http_www_eurekaselect_com_openurl_content_php_genre_article_issn_1574_8871_volume_11_issue_4_spage_2900 | ||
| 035 | |a (KEY)0598973620160000011000400290hivvaccineforpreventionandcureamissionpossible | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ZDB |
| 100 | 0 | |a Da-Yong Lu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HIV Vaccine for Prevention and Cure, A Mission Possible |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a HIV/AIDS was once a highly deadly infective disease that killed the global people of a million annually two decades ago. While we are enjoying the HIV therapeutic advances (mostly important from HAART invention), one obvious drawback is still unresolved-unable to clearance all HIV from infected human bodies. As a result, a series of different therapeutic attempts have been proposed based on present knowledge of different features of HIV-induced pathogenesis and human mortalities. Facing this shortcoming, innovative designs and update of HIV vaccines and other types of HIV therapeutic inventions can be a final solution for completely HIV clearance and infection managements in human beings. Owing to these scientific and medical significances, several experimental and clinical attempts have to be made. Among these attempts, part of them (updating HIV vaccine developments and clinical routines) are quite promising and noteworthy. In this article, we offer the general information of this attempt and discuss it separately, especially on the respects of HIV vaccine strategic innovations. | ||
| 700 | 0 | |a Hong-Ying Wu |4 oth | |
| 700 | 0 | |a Jian Ding |4 oth | |
| 700 | 0 | |a Nagendra Sastry |4 oth | |
| 700 | 0 | |a Ting-Ren Lu |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Reviews on recent clinical trials |d Saif Zone, Sharjah [u.a.] : Bentham, 2006 |g 11(2016), 4, Seite 290-296 |w (DE-627)518259552 |w (DE-600)2251879-4 |x 1574-8871 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2016 |g number:4 |g pages:290-296 |
| 856 | 4 | 2 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1574-8871&volume=11&issue=4&spage=290 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2016 |e 4 |h 290-296 | ||